Option chain shows key data for Kintor Pharmaceutical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Kintor Pharmaceutical.

Kintor Pharmaceutical (OTC:KNTPF) Stock, Option Chain

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.

Biotech

News

Penny Stocks

Small Cap

General

BGNE

BTAI

CCCC

CTXR

INCY

IOVA

INNOVENT BIOLOGICS INC by Innovent Biologics Inc.

IVBXF

KNTPF

LBPH

RLMD

SRRK

STSA

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: BioXcel&#39;s Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

KINTOR PHARMACEUTICAL by KINTOR PHARMACEUTICAL LTD.

Kintor Pharmaceutical Ltd

Kintor Pharmaceutical

Comments

Kintor Pharmaceutical

Kintor Pharmaceutical (KNTPF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell